Takeda Bigs Up Entyvio As Pillar Of GI Plans
This article was originally published in PharmAsia News
Amid generic challenges to some of its older mainstay products in the field, Takeda is aiming to convince investors that its commitment to, and prospects in, the gastrointestinal (GI) space remain solid.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.